Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2023 Jan 26

PMID 36702340

Authors

L Parker Gregg

David J Ramsey

Julia M Akeroyd

Shehrezade A Jafry

Michael E Matheny

Salim S Virani

Sankar D Navaneethan

Affiliations

Soon will be listed here.

Abstract

Rationale & Objective: Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD). We evaluated factors associated with SGLT2 inhibitor prescription, disparities by race and sex, and facility-level variation in prescription patterns.

Study Design: Retrospective cohort.

Setting & Participants: A national sample of US veterans with comorbid T2DM, CKD, and ASCVD with a primary care visit between January 1 and December 31, 2020.

Exposure: Race, sex, and individual Veterans Affairs (VA) location.

Outcome: SGLT2 inhibitor prescription.

Analytical Approach: Multivariable logistic regression assessed associations of race and sex with SGLT2 inhibitor prescription. Facility-level variation in SGLT2i prescription was quantified by median rate ratios (MRR), which express the likelihood that 2 randomly selected facilities differ in their use of SGLT2 inhibitor among similar patients.

Results: Of 174,443 patients with CKD, T2DM, and ASCVD, 20,024 (11.5%) were prescribed an SGLT2 inhibitor. Lower odds of SGLT2 inhibitor prescription were seen in Black or African American patients compared with White patients (OR, 0.87 [95% CI, 0.83-0.91]) and among women compared with men (OR, 0.59 [95% CI 0.52-0.67]). The adjusted MRR for SGLT2 inhibitor prescription was 1.58 (95% CI 1.48-1.67) in the total cohort, indicating an unexplained 58% variation in treatment between VA facilities, independent of patient and facility characteristics. Facility-level variation was evaluated among Black or African American patients (MRR, 1.55 [95% CI 1.41-1.68]), White patients (MRR, 1.57 [95% CI 1.47-1.66]), women (MRR, 1.40 [95% CI 1.28-1.51]), and men (MRR, 1.57 [95% CI 1.48-1.67]).

Limitations: Albuminuria was not assessed.

Conclusions: Prescription for SGLT2 inhibitors was low among likely eligible patients, with evident disparities by sex and race and between individual VA facilities. Efforts are needed to study and address the reasons for these disparities to improve equitable adoption of these important medications.

Citing Articles

Breaking Barriers: Tackling Racial and Socioeconomic Disparities in the Prescription of Life-Saving SGLT2 Inhibitors for Proteinuria.

Taylor S, Zinabu S, McMillan E, Ocampo E, Edmonds A, Lyles S Cureus. 2025; 17(1):e77159.

PMID: 39925502 PMC: 11805696. DOI: 10.7759/cureus.77159.

Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics.

Minutolo R, Borrelli S, Ambrosini A, Amoroso L, Aucella F, Batini V Clin Kidney J. 2025; 18(1):sfae396.

PMID: 39834621 PMC: 11744308. DOI: 10.1093/ckj/sfae396.

Prevention of cardiovascular disease in women with type 2 diabetes: the role of incretin mimetics and sodium-glucose cotransporter-2 inhibitors.

Ibrahim E, Burken M, Lastra G, Manrique-Acevedo C Am J Physiol Cell Physiol. 2024; 328(1):C315-C322.

PMID: 39672547 PMC: 11901335. DOI: 10.1152/ajpcell.00765.2024.

Unraveling Sex Differences in Kidney Health and CKD: A Review of the Effect of Sex Hormones.

van Eeghen S, Nokoff N, Vosters T, Oosterom M, Oosterom-Eijmael M, Cherney D Clin J Am Soc Nephrol. 2024; .

PMID: 39671256 PMC: 11835196. DOI: 10.2215/CJN.0000000642.

Chronic kidney disease in older adults: challenges and opportunities for the primary care provider.

Brady B, Suffoletto J, Sankary R, Chertow G BMC Prim Care. 2024; 25(1):388.

PMID: 39487419 PMC: 11529074. DOI: 10.1186/s12875-024-02638-4.

References

Inoue D, Nishi H, Inoue R, Nangaku M . Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. Int Heart J. 2021; 62(3):592-600. DOI: 10.1536/ihj.20-716. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Nelson A, Ardissino M, Haynes K, Shambhu S, Eapen Z, McGuire D . Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2021; 10(2):e016835. PMC: 7955303. DOI: 10.1161/JAHA.120.016835. View

Kraus B, Weir M, Bakris G, Mattheus M, Cherney D, Sattar N . Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2020; 99(3):750-762. DOI: 10.1016/j.kint.2020.10.031. View

Al Rifai M, Mahtta D, Ramsey D, Lee M, Krittanawong C, Navaneethan S . Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2021; 248:160-162. DOI: 10.1016/j.ahj.2021.12.006. View

de Boer I, Khunti K, Sadusky T, Tuttle K, Neumiller J, Rhee C . Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45(12):3075-3090. PMC: 9870667. DOI: 10.2337/dci22-0027. View

Mahtta D, Ramsey D, Lee M, Chen L, Al Rifai M, Akeroyd J . Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022; 45(2):372-380. PMC: 8914426. DOI: 10.2337/dc21-1815. View

10.

Limonte C, Hall Y, Trikudanathan S, Tuttle K, Hirsch I, de Boer I . Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complications. 2022; 36(6):108204. DOI: 10.1016/j.jdiacomp.2022.108204. View

11.

Xie Y, Bowe B, Gibson A, McGill J, Maddukuri G, Al-Aly Z . Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. J Am Heart Assoc. 2021; 10(11):e020237. PMC: 8483543. DOI: 10.1161/JAHA.120.020237. View

12.

Lamprea-Montealegre J, Madden E, Tummalapalli S, Peralta C, Neilands T, Garcia P . Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022; 328(9):861-871. PMC: 9449794. DOI: 10.1001/jama.2022.13885. View

13.

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D . Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24):2295-2306. DOI: 10.1056/NEJMoa1811744. View

14.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

15.

Maitra N, Mahtta D, Navaneethan S, Vaughan E, Kochar A, Gulati M . A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?. Curr Cardiol Rep. 2022; 24(6):689-698. DOI: 10.1007/s11886-022-01694-5. View

16.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

17.

. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S):S1-S115. DOI: 10.1016/j.kint.2020.06.019. View

18.

Arnold S, de Lemos J, Rosenson R, Ballantyne C, Liu Y, Mues K . Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019; 140(7):618-620. DOI: 10.1161/CIRCULATIONAHA.119.041730. View

19.

Chu C, Powe N, McCulloch C, Banerjee T, Crews D, Saran R . Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria. Hypertension. 2020; 77(1):94-102. PMC: 7725867. DOI: 10.1161/HYPERTENSIONAHA.120.16281. View

20.

McCoy I, Han J, Montez-Rath M, Chertow G, Rhee J . Patient and Provider Characteristics Associated With Sodium-Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. Clin Diabetes. 2020; 38(3):240-247. PMC: 7364452. DOI: 10.2337/cd19-0087. View